Becton Dickinson and (NYSE:BDX) Price Target Raised to $298.00 at KeyCorp

Becton Dickinson and (NYSE:BDX) had its price objective hoisted by KeyCorp from $284.00 to $298.00 in a report published on Wednesday morning, BenzingaRatingsTable reports. They currently have an overweight rating on the medical instruments supplier’s stock.

Several other research analysts have also commented on BDX. Stifel Nicolaus lifted their price target on shares of Becton Dickinson and from $275.00 to $295.00 and gave the company a buy rating in a report on Monday, December 16th. JPMorgan Chase & Co. lifted their price target on shares of Becton Dickinson and from $285.00 to $300.00 and gave the company an overweight rating in a report on Friday, December 20th. Barclays lowered shares of Becton Dickinson and from an overweight rating to an equal weight rating and set a $275.00 price target for the company. in a report on Wednesday, January 8th. Finally, Morgan Stanley boosted their target price on shares of Becton Dickinson and from $261.00 to $287.00 and gave the company an equal weight rating in a research note on Tuesday, December 17th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average price target of $281.90.

NYSE BDX opened at $278.25 on Wednesday. Becton Dickinson and has a one year low of $221.47 and a one year high of $280.56. The company has a 50-day simple moving average of $271.36 and a 200-day simple moving average of $257.19. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.72 and a current ratio of 1.18. The firm has a market capitalization of $75.39 billion, a PE ratio of 71.35, a price-to-earnings-growth ratio of 1.99 and a beta of 1.07.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The business had revenue of $4.58 billion during the quarter, compared to analyst estimates of $4.57 billion. During the same period in the previous year, the business posted $2.93 EPS. The company’s quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts forecast that Becton Dickinson and will post 12.57 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 1.14%. This is a positive change from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date was Monday, December 9th. Becton Dickinson and’s payout ratio is presently 27.05%.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 13,860 shares of the business’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $275.19, for a total transaction of $3,814,133.40. Following the completion of the transaction, the chief executive officer now directly owns 227,647 shares of the company’s stock, valued at approximately $62,646,177.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vincent A. Forlenza sold 19,675 shares of the business’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $275.15, for a total transaction of $5,413,576.25. Following the transaction, the chief executive officer now directly owns 227,647 shares of the company’s stock, valued at $62,637,072.05. The disclosure for this sale can be found here. Insiders have sold a total of 91,231 shares of company stock valued at $24,787,690 over the last three months. 0.12% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the business. Allworth Financial LP raised its position in shares of Becton Dickinson and by 386.4% during the 3rd quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 85 shares in the last quarter. Northwest Investment Counselors LLC bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth about $27,000. Liberty Wealth Management LLC raised its position in shares of Becton Dickinson and by 293.1% during the 3rd quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 85 shares in the last quarter. CX Institutional bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth about $31,000. Finally, North Star Investment Management Corp. bought a new stake in shares of Becton Dickinson and during the 3rd quarter worth about $45,000. Institutional investors own 84.49% of the company’s stock.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: New Google Finance Tool and Screening Stocks

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.